Natco Pharma Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Natco Pharma Limited
The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.
Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues
The US Court of Appeals rejected all arguments brought by Alvogen and Natco in their appeal against an unfavorable lower court Imbruvica (ibrutinib) ruling, leaving the ANDA sponsors facing a significant wait to potential approval and launch.
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
- Generic Drugs